GSK stock forecast, quote, news & analysis

Key Takeaways

• GSK shares traded near $51.35 in late July 2026, down approximately 2.2% over the preceding 30 days, reflecting a mixed period of major strategic moves and pipeline setbacks.
• The $10.6 billion acquisition of Nuvalent, completed July 15, adds two late-stage lung cancer assets under FDA review with decision dates in September and November 2026, marking GSK's largest-ever oncology deal.
• GSK discontinued development of camlipixant for chronic cough on July 17 after mixed Phase III results, removing a drug once projected to generate over £2.5 billion in peak annual sales.
• Q1 2026 results showed 5% sales growth at constant exchange rates and 10% core operating profit growth, driven by a 14% surge in Specialty Medicines.
• Q2 2026 earnings and a Capital Markets Day are scheduled for July 28, where new CEO Luke Miels is expected to outline his strategic vision and path toward the £40 billion 2031 revenue target.
• Analyst consensus remains Hold, though Jefferies recently resumed coverage with a Buy rating and a 2,500p price target, citing oncology pipeline potential.

Current Market Snapshot

GSK plc shares have been rangebound in recent weeks as the market digests a rapid succession of high-impact corporate developments. The stock closed at $51.35 on July 24, 2026, representing a modest decline of roughly 2.2% from levels seen approximately 30 days earlier. Year-to-date, the stock has gained approximately 3.3%, following a strong rally in the second half of 2025 and early 2026 that pushed shares above £20 in London for the first time in more than two decades. Broader pharmaceutical sector sentiment has been shaped by a rotation of capital toward AI-linked sectors, while GSK-specific catalysts — including the record Nuvalent acquisition, the camlipixant clinical disappointment, and anticipation of the upcoming Capital Markets Day — have kept the stock in a holding pattern ahead of key catalysts in the second half of the year.

GSK plc (GSK) Business Overview and Competitive Position

GSK is a global biopharmaceutical company headquartered in London, organized around three core segments: Specialty Medicines, Vaccines, and General Medicines. Specialty Medicines — spanning HIV, respiratory/immunology, and oncology — is the primary growth engine, contributing £3.2 billion in Q1 2026 sales. The HIV portfolio, managed through the majority-owned ViiV Healthcare joint venture, remains the largest single contributor, with long-acting injectables Cabenuva and Apretude driving double-digit growth. In vaccines, Shingrix continues to dominate the shingles market with over £1 billion in quarterly sales. The company generates approximately 52% of its revenue in the United States, making it particularly sensitive to U.S. pricing policy and regulatory developments. Under new CEO Luke Miels, who succeeded Emma Walmsley in January 2026, GSK is intensifying its focus on oncology while managing the approaching loss of exclusivity on blockbuster HIV drug dolutegravir beginning in 2028.

Recent Developments Driving GSK

The most consequential development in recent weeks was the July 15 completion of GSK's $10.6 billion acquisition of Nuvalent, a Boston-based clinical-stage biopharmaceutical company. The deal brings three lung cancer assets into GSK's oncology portfolio: zidesamtinib and neladalkib, two next-generation ROS1 and ALK inhibitors currently under FDA review with target decision dates of September 18 and November 27, 2026, respectively, and NVL-330, a HER2 inhibitor in Phase I trials. Both lead candidates have received FDA Breakthrough Therapy and Orphan Drug Designations and, if approved, are expected to launch in 2026 with multi-blockbuster potential. Jefferies analysts called neladalkib the bigger prize, modeling potential sales of $2.4 billion by 2034.

Just two days later, on July 17, GSK announced it would discontinue development of camlipixant for refractory chronic cough after the drug delivered mixed results across two Phase III studies. While the higher 50 mg dose met the primary endpoint in a 12-week study, it failed to replicate that result in a 24-week trial, and secondary endpoints were missed across both doses. GSK had acquired the asset through its $2 billion purchase of Bellus Health in 2023 and had projected peak annual sales exceeding £2.5 billion. Shares fell as much as 4.5% on the news, and J.P. Morgan analysts suggested a write-down on the program was likely.

On the regulatory front, the FDA recently approved Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer. Meanwhile, bepirovirsen — a potential functional cure for chronic hepatitis B — has regulatory filings accepted in the U.S., EU, China, and Japan, with a U.S. PDUFA date of October 26, 2026. In analyst coverage, Jefferies resumed GSK with a Buy rating and 2,500p price target, while HSBC upgraded the stock to Hold, citing improving pipeline reinvestment under the new CEO.

Trending AI Robots

Investors seeking to complement their analysis of stocks like GSK may benefit from exploring algorithmic trading strategies. Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI-powered trading bots drawn from a universe of hundreds of automated strategies trading across thousands of tickers. These bots employ a range of methodologies — from short-term momentum tactics to longer-duration trend-following approaches — and are ranked based on verified performance metrics. The curated section highlights only the most relevant and consistently performing bots, offering traders a filtered view into algorithmic trading opportunities. Browsing the Trending AI Robots page can provide a useful lens into how AI-driven systems are navigating current market conditions.

2026 Outlook and What Investors Should Watch

The second half of 2026 presents a dense calendar of catalysts that could materially shape GSK's investment narrative. First and foremost, the July 28 Capital Markets Day under CEO Luke Miels will be closely scrutinized for how management plans to bridge the estimated £4 billion-plus gap between consensus analyst forecasts and the company's £40 billion 2031 revenue target. Investors will look for pipeline reprioritization details following the Nuvalent acquisition and a clearer articulation of cost-efficiency measures.

Two FDA decision dates in oncology — zidesamtinib on September 18 and neladalkib on November 27 — represent potential near-term value drivers. A bepirovirsen approval decision is expected in October. Additional pivotal readouts anticipated in the second half include Jemperli in rectal cancer, Exdensur for EGPA, and data on a three-times-yearly HIV PrEP regimen. On the macroeconomic side, GSK has secured a U.S. pricing agreement that trades lower drug prices for relief from potential Section 232 tariffs through early 2029, reducing a key policy uncertainty. The looming dolutegravir patent cliff beginning in 2028 remains the most significant structural risk, making the commercial execution of newer oncology and specialty assets essential to sustaining long-term growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations